HCAT
Health Catalyst, Inc.
HCAT lost money over the past year, so it has no meaningful PE right now. Analysts expect a turn to a loss, though they disagree widely on how much.
HCAT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Healthy | |
| Unavailable |
HCAT's cash flow is currently healthy, but its revenue and profitability are under pressure. There isn't enough data to rate its balance sheet.
HCAT PE Valuation
HCAT has no meaningful PE right now: it lost money over the past year.
HCAT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect HCAT's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
HCAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.84 | -$1.25 |
| Q2 2026 | -$3.69 | -$2.18 |
| Q1 2026 | -$3.73 | -$2.58 |
| Q4 2025 | -$2.55 | -$1.40 |
| Q3 2025 | -$1.59 | -$0.25 |
| Q2 2025 | -$1.51 | -$0.02 |
| Q1 2025 | -$1.15 | +$0.69 |
| Q4 2024 | -$1.15 | +$0.94 |
HCAT lost $2.84 per share over the past year, a bigger loss than the year before.
HCAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $56.3M | -26% |
| Q2 2026 | $70.5M | -13% |
| Q1 2026 | $70.8M | -11% |
| Q4 2025 | $74.7M | -6.2% |
| Q3 2025 | $76.3M | 0% |
| Q2 2025 | $80.7M | +6.3% |
| Q1 2025 | $79.4M | +6.3% |
| Q4 2024 | $79.6M | +6% |
HCAT's revenue has slid since its 2025 peak: $56M last quarter, down 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 89% | +112 points |
| Q2 2026 | -52% | -5.8 points |
| Q1 2026 | -150% | -125 points |
| Q4 2025 | -115% | -93 points |
| Q3 2025 | -23% | -5 points |
| Q2 2025 | -46% | -25 points |
| Q1 2025 | -25% | +5.1 points |
| Q4 2024 | -22% | +22 points |
HCAT's operating margin was 89% last quarter, up 112 points from the same quarter a year ago, near the top of its range since 2019.
HCAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2M | -$1.3M |
| Q2 2026 | -$70K | +$8.7M |
| Q1 2026 | $18.2M | +$18.6M |
| Q4 2025 | $9.6M | +$13.6M |
| Q3 2025 | -$719K | -113% |
| Q2 2025 | -$8.8M | -763% |
| Q1 2025 | -$390K | -104% |
| Q4 2024 | -$3.9M | +$15.4M |
HCAT's free cash flow has turned positive again: $26M over the past year, against −$14M the year before.
HCAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +2M shares |
| 1 year | +7.9% | +5.6M shares |
| 3 years | +34% | +19.2M shares |
| 5 years | +55% | +26.9M shares |
| Available history | +105% | +38.8M shares |
HCAT has 76M diluted shares, up 7.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $5M |
| Q4 2024 | — |
HCAT hasn't bought back shares in the past year.
HCAT Net Leverage
HCAT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HCAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.4 | Neutral |
| Stochastic | 9.3 | Oversold |
HCAT's weekly RSI is 37 (neutral) and its Stochastic is 9 (oversold).
HCAT PE vs Healthcare Sector
HCAT has no meaningful PE right now: it lost money over the past year.
HCAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.65 | 18% below |
| 20 week MA | $1.79 | 24% below |
| 50 week MA | $1.79 | 24% below |
| 100 week MA | $2.93 | 54% below |
| 200 week MA | $6.18 | 78% below |
HCAT is in a downtrend: it's below all five of its weekly moving averages, and 78% below its 200-week average.
HCAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $34.1 | $44.9 | +31% |
| 2021 | $44.9 | $39.5 | -12% |
| 2022 | $39.5 | $10.3 | -74% |
| 2023 | $10.3 | $9.26 | -10% |
| 2024 | $9.26 | $7.08 | -24% |
| 2025 | $7.08 | $2.42 | -66% |
| 2026 YTD | $2.42 | $1.36 | -44% |
HCAT has finished five years in a row lower, and it's down 44% so far in 2026.